Axsome Therapeutics, Inc. (Nasdaq: AXSM) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, Feb. 22, 2016 --

What: 

Axsome Therapeutics, Inc. (Nasdaq:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will visit the Nasdaq MarketSite in Times Square to celebrate its initial public offering (IPO) on November 19, 2015.

In honor of the occasion, Herriot Tabuteau, M.D., Chief Executive Officer, and other members of the Axsome team will ring the Opening Bell. 

Where:

Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:

Tuesday, February 23, 2016 – 9:15 a.m. to 9:30 a.m. ET 

Axsome Therapeutics Media Contact: 
Mark Jacobson
(212) 332-3243 
[email protected]

Nasdaq MarketSite: 
Emily Pan
(646) 441-5120 
[email protected]

Feed Information: 
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page:

http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit our Tumblr Page:

http://nasdaq.tumblr.com/

Webcast:
A LiveStream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders. Axsome’s product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05. AXS-02 is currently in a Phase 3 trial in complex regional pain syndrome (CRPS), with additional Phase 3 trials planned in knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP) associated with Modic changes (MCs). A Phase 3 trial in treatment resistant depression (TRD) is currently planned with AXS-05. AXS-02 and AXS-05 are investigational and are not yet approved. No claims on the safety or efficacy of these product candidates are supported by the FDA..

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-